Reference : Development of new thrombolytic agents using recombinant DNA technology.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Development of new thrombolytic agents using recombinant DNA technology.
Pierard, Luc mailto [Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation >]
Bollen, A. [> >]
Journal of Biotechnology
Yes (verified by ORBi)
[en] Amino Acid Sequence ; Animals ; DNA, Recombinant ; Fibrinolysis/physiology ; Fibrinolytic Agents ; Humans ; Molecular Sequence Data ; Plasminogen Activators/genetics ; Recombinant Proteins/biosynthesis/genetics/pharmacology
[en] The increasing incidence of thromboembolic diseases has sustained the search for new agents able to stimulate the natural fibrinolytic system. The first generation of antithrombotic agents include bacterial streptokinase and human urine urokinase. Because these molecules lack specificity for the fibrin clot, important efforts have been made to produce, using recombinant DNA technology, agents presenting higher fibrin clot selectivity such as t-PA (tissue-type plasminogen activator) and scu-PA (single chain urokinase-type plasminogen activator). In parallel, several laboratories are presently attempting to create mutants and hybrids plasminogen activators displaying improved thrombolytic properties with respect to the natural molecules. In this paper, we describe briefly the mechanisms of fibrinolysis and the role of the different natural thrombolytic agents. In addition, we review the possibilities of genetic engineering for the production of natural and novel plasminogen activators.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.